
==== Front
Med Int (Lond)
Med Int (Lond)
MI
Medicine International
2754-3242
2754-1304
D.A. Spandidos

MI-4-6-00193
10.3892/mi.2024.193
Articles
Association of iron deficiency anaemia with the hospitalization and mortality rate of patients with COVID‑19
Jalal Mohammed M. 1
Algamdi Maaidah M. 2
Alkayyal Almohanad A. 1
Altayar Malik A. 1
Mouminah Amr S. 3
Alamrani Ahlam Jumaa 2
Althaqafi Nouf Abdulaziz 2
Alamrani Reem Ali 2
Alomrani Wjdan Salem 2
Alemrani Yasmin Attallah 2
Alhelali Marwan 4
Elfaki Imadeldin 5
Mir Rashid 1
1 Department of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia
2 Faculty of Nursing, Community and Mental Health Nursing Department, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia
3 Neuroscience Center, King Abdullah Medical Complex, Jeddah 23816, Kingdom of Saudi Arabia
4 Department of Statistics, Faculty of Science, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia
5 Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia
Correspondence to: Dr Rashid Mir, Department of Medical Laboratory Technology, Prince Fahad Bin Sultan Chair for Biomedical Research, Faculty of Applied Medical Sciences, University of Tabuk, 47512 King Faisal Road, Tabuk 71491, Kingdom of Saudi Arabia drsadia@uitm.edu.my rashidmirtabuk@gmail.com
Nov-Dec 2024
10 9 2024
10 9 2024
4 6 6909 5 2024
26 8 2024
Copyright: © 2024 Jalal et al.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) illness led to the coronavirus disease 2019 (COVID-19) pandemic, which has caused enormous health and financial losses, as well as challenges to global health. Iron deficiency anaemia (IDA) has been linked to adverse outcomes in patients infected with SARS-COV-2. The present study aimed to assess the association between IDA and the severity of COVID-19 in hospitalized patients. For this purpose, a retrospective data analysis of 100 patients with COVID-19 was conducted. Data of patients hospitalized with SARS-COV-2 infection confirmed by RT-PCR were collected between June, 2021 and March, 2022. The collected data included patient demographics, comorbidities, clinical signs, symptoms and IDA medical laboratory findings, including complete blood count and iron profiles. The results revealed that patients with COVID-19 admitted to the isolation unit represented 61.0% of the study sample, whereas 39.0% were admitted to the intensive care unit (ICU). No patients had stage I IDA, whereas 4 patients (4%) had stage II IDA. Furthermore, 19 patients (19.0%) had stage III IDA. A significantly higher proportion of patients with IDA (69.6%) were admitted to the ICU compared with those without IDA (29.9%, P<0.001). Additionally, patients with IDA had a higher proportion of a history of stroke compared with those without IDA (17.4 vs. 2.6%, respectively, P=0.024). The most common comorbidities identified were hypertension (29%), diabetes (23%) and heart problems (17%). On the whole, the present study demonstrates significant associations between IDA and a longer hospitalization period. A greater incidence of complications was observed in the hospitalized patients who were SARS-COV-2-positive. Although further studies with larger sample sizes are required to confirm these findings, the results presented herein may provide insight for physicians as regards the prevention and treatment of patients with IDA who are infected with coronavirus.

iron deficiency anaemia
coronavirus disease 2019
hospitalization
Middle East respiratory syndrome coronavirus
severe acute respiratory syndrome coronavirus 2
Funding: No funding was received.
==== Body
pmcIntroduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused the continuing coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to health worldwide and the global economy (1). The outbreak of coronavirus originating in December, 2019 was termed SARS-CoV-2 by the World Health Organization (WHO) and the associated disease was named COVID-19(2). By the middle of February 2022, there were over 422 million confirmed cases of COVID-19 confirmed worldwide as per the WHO (3). Moreover, 5.8 million related deaths have occurred due to this disease. Since the time first case of COVID-19 identified in Saudi Arabia on March 2, 2020, the Saudi Ministry of Health has reported 734,389 cases by February 17, 2022, and this included 8,977 related deaths (4,5). Owing to the clinical course of COVD-19 as a subclinical infection, its long incubation period and convalescence, COVID-19 was declared as public health emergency at a global level by the WHO (6). There is a lack of defined treatment protocols for COVID-19, essentially warrants controlling of transmission (7,8). Yet, hospitalization is required in ~20% of symptomatic patients, with 2-5% of patients later requiring management in intensive care units (ICUs) with mechanical ventilation (9,10).

In individuals who are at an advanced age and who have comorbidities, the frequency of hospitalisation, ICU admission and mechanical breathing is markedly higher (11,12,13). Characteristic features of severe infection with COVID-19 include a hyper-inflammatory condition that involves augmented levels of inflammation markers, such as IL-6 and CRP, and increased levels of ferritin (14,15). Ferritin has proven to be the key iron storage protein. Inflammation or iron loading is known to induce the expression of ferritin. In the case of individuals with COVID-19, abnormalities in the concentration of ferritin are associated with the severity of the disease, the development of acute respiratory distress syndrome and mortality (9,14,16). It is well recognised that inflammation alters iron homeostasis. The most common changes include the augmented acquisition of iron, as well as retention inside macrophages and the decreased absorption of iron inside the intestine (17). This leads to a reduced concentration of iron in the circulation and low levels of iron available for erythropoiesis, a process that is required to generate haemoglobin (Hb). In combination with cytokine-mediated erythropoiesis inhibition, the reduced half-life of erythrocytes and diminished erythropoietin activity, this leads to the development of anaemia of inflammation (AI) (18). Low levels of iron and transferrin in the circulation and the diminished saturation of transferrin with iron have been proven to be the characteristic features of AI. However, the ferritin concentration remains at a normal or higher level. Due to this fact, AI differs from iron deficiency anaemia (IDA), which is defined by low ferritin levels, along with elevated transferrin levels (18,19).

Researchers have demonstrated a link between anaemia and worse clinical outcomes of patients with a number of illnesses, including infections and inflammatory diseases (20,21). Reduced levels of iron in the body and increased levels of tissue iron are linked to a reduced lung activity, as well as to severe inflammation of the pulmonary system (22). Anaemia has been proven to be a common manifestation in individuals infected with COVID-19. According to reports, >60% of cases of anaemic COVID-19 have been found to have considerably more adverse outcomes in comparison to COVID-19 cases that were not anaemic (23,24). The WHO has described anaemia as a condition with a Hb level <13 g/dl in males and 12 g/dl in females (25). It has been suggested that the levels of Hb and ferritin are associated with the COVID-19 severity, and that iron metabolism and anaemia affect the pathogenicity, prognosis and treatment of patients with COVID-19 (23,26). Therefore, the present study aimed to examine the association between IDA upon admission to hospital and the outcomes of patients with COVID-19 admitted to King Fahad Specialist Hospital, Tabuk, Kingdom of Saudi Arabia. The present study was conducted in an aim to assess the association between IDA and COVID-19 positivity, as well as severity.

Patients and methods

Study design and population

A retrospective data analysis study was conducted at King Fahad Specialist Hospital, Tabuk, Kingdom of Saudi Arabia, which included 100 patients diagnosed with COVID-19 based on the real time-polymerase chain reaction (RT-PCR) confirmation of SARS-COV-2 between June, 2021 and March, 2022. The study followed guidelines from the WHO and the Ministry of Health in the Kingdom of Saudi Arabia for the diagnosis of patients with COVID-19. Outcomes, mortality and length of stay were all reported for all enrolled patients.

Data collection and sampling

Data for the present study were extracted from the hospital records using a unique medical record number for each patient and were reviewed and examined by a medical team. The extracted data included patient demographics, comorbidities, clinical signs, symptoms, and IDA laboratory findings, including complete blood count and iron profiles. These laboratory examinations were interpreted by the attending physicians. Subjects who tested positive for COVID-19 by RT-PCR in the age group of 18 to 65 years were included in the study; mortal cases due to COVID-19-related complications were also included. Subjects with negative RT-PCR testing for COVID-19, children, subjects with haemorrhagic complications and patients over 65 years old were excluded from the study.

Ethical considerations

The present study was conducted according to the guidelines outlined in the Declaration of Helsinki and received two ethical approvals from the University of Tabuk Research Ethics Committee (Tabuk, Saudi Arabia; Registration no. UT-198-52-2022) and from the Institutional Review Board General Directorate of Health Affairs, Tabuk Region (Registration no. 612-43-006198). Ethical approvals include agreement for data gathering using data collection forms that include only laboratory results and are organized by unique numbers. No personal Identifier was required, anonymity and confidentiality were maintained as data were accessed and collected by the authors' research team. The need for informed consent for this study was waived by the local ethics research committee, as the present retrospective study using existing data and the subjects cannot be identified directly or indirectly.

Study variables

The present study assessed the association between IDA and the outcomes of patients with COVID-19 as regards the length of hospitalization and mortality rates. This yielded the following variables: i) COVID-19 mortality rate; ii) COVID-19 hospitalization; iii) IDA.

Research tools

The authors used four forms to extract data from the patients admitted to the King Fahad Specialist Hospital, Tabuk, Saudi Arabia with a PCR test result confirming SARS-COV-2 infection between June, 2021 and March, 2022. The data were retrieved from the Johns Hopkins patient history form and designated by the authors to fulfil the data required for the study. The data were divided into three forms, as presented in Data S1 (Parts A-C). The first form (Part A) includes the admission data and the outcomes of the medical interventions during the hospitalization period. The second form (Part B) includes data regarding the previous medical history of the participants, including chronic diseases and/or previous major surgeries. The third form (Part C) indicates the laboratory test results, including a PCR swab for COVID-19, complete blood count and iron indices to confirm IDA. The criteria for IDA were adapted from previously published literature (27). The diagnostic criteria for IDA include the following serum markers: Decreased haemoglobin levels (<130 g/l in males; <120 g/l in females; and <110 in pregnant females); a ferritin level of 130 µg/l (no inflammation) and 100 µg/l (in patients with inflammation); the levels of transferrin and the total iron binding capacity are also increased, while the iron level is decreased, the mean corpuscular volume is low, and the transferrin saturations are <20% (27).

Statistical analysis

Statistical analysis was carried out using RStudio (version 4.1.1) software. Qualitative data are expressed as frequencies and percentages, whereas quantitative data are presented as the median and interquartile range (IQR). The study groups were divided based on the status of IDA. Differences between groups were analysed using Pearson's Chi-squared test or Fisher's exact test for categorical data, whenever applicable. Additionally, the difference in hospitalization period (only) was assessed using the Wilcoxon rank sum test. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Demographic characteristics and patterns of comorbidities

The present study included the records of 100 patients with a confirmed COVID-19 infection. More than half of the patients were females (55.0%) and 41.0% of the patients were aged 45 to <60 years. Patients admitted to the isolation unit represented 61.0% of the sample size, whereas 39.0% of them were admitted to the ICU. The most common comorbidities included hypertension (29.0%), diabetes (23.0%) and heart problems (17.0%) (Table I). Approximately half of the patients had low haemoglobin levels (51.0%) and a low red blood cell (RBC) count (46.0%). The serum iron concentration was low among 40.0% of the patients. The transferrin concentration was low among 42.0% of the patients, and transferrin saturation was low among 41.0% of patients. The characteristics of other blood indices are listed in Table II.

Characteristics of iron deficiency and the differences between the study groups

The number of patients with IDA was 23 patients (23%). A significantly higher proportion of patients with IDA (69.6%) were admitted to the ICU compared with those without IDA (29.9%; P<0.001). Additionally, the patients with IDA had a higher proportion of a history of stroke compared with those without IDA (17.4 vs. 2.6%; P=0.024) (Table I).

Presenting symptoms and diagnosis upon admission

The most common presenting symptom among the included patients was cough (25.0%), followed by shortness of breath (20.0%), high blood pressure (12.0%) and fever (10.0%). The rate of cough was significantly lower among patients with IDA than those without IDA (4.3 vs. 31.2%; P=0.009). However, the proportion of patients presenting with high blood pressure was significantly higher among the patients with IDA (26.1 vs. 7.8%; P=0.028) (Table III).

Outcomes of the patients

The median (IQR) period of hospitalization among the study cohort was 7 days (4 to 15 days), and the patients with IDA had a significantly longer period of hospitalization (median, 15 days; IQR, 8 to 22 days) than those without IDA (median, 5 days; IQR, 3 to 10 days; P<0.001) (Table IV). Generally, 52.0% of the patients were discharged without complications. The proportion of patients who were discharged without complications was significantly lower among the patients with IDA compared with those without IDA (26.1 vs. 59.7%, P=0.005) (Tables IV and V). No significant differences were noted among the IDA and no-IDA cohorts in terms of the rates of other complications, as well as in the rate of mortality (Table V).

Discussion

It has been demonstrated that >90% of hospitalized patients with COVID-19 have exhibited reduced blood iron levels (28), and that 30% of patients still had iron insufficiency at 60 days following the onset of COVID-19(28). Mutations in the homeostatic iron regulator (HFE) gene have been reported to be associated with COVID-19 (29,30). The HFE gene encodes the hemochromatosis protein. This protein plays a crucial role in iron metabolism and homeostasis (31).

The present study examined the association between IDA and COVID-19. For this purpose, the data of 100 patients with COVID-19 from the King Fahad Specialist Hospital were collected. Of these 100 patients, 11% patients did not survive, and 61.0 and 39.0% of patients were admitted to the isolation unit and ICU, respectively. Moreover, cardiovascular disorders, diabetes and hypertension were the most prevalent comorbidities among these patients with COVID-19.

IDA is a condition characterized by a reduced concentration of iron. Reduced iron levels may result in the diminished generation of RBCs that transport oxygen to tissues of the body (32). In general, IDA occurs due to inadequate consumption and the absorption of iron and/or loss of this metal due to bleeding (33). Even though the mechanisms through which anaemia augments the susceptibility of an individual to developing infectious disorders remain unclear, and these may involve a number of other factors, such as immunity. IDA affects the health of an individual. In the present study, 23 patients suffered from IDA, indicating an association of IDA with the highest severity of the condition. After analysing the data, it was found that the patients with IDA had greater susceptibility for admission to the ICU in comparison to patients with COVID-19 who did not have IDA. Moreover, the patients with IDA had a longer period of hospitalization. Similarly, a decreased number of patients with IDA were discharged from the hospital without any complications. These results indicated that IDA needs to be considered and treated, particularly in patients suffering from infectious disorders, such as COVID-19.

According to the study conducted by Lechuga et al (34), long-term COVID-19 is linked to a number of persistent haematological changes, including changes in RBC composition, anaemia, lymphocytopenia and higher concentrations of inflammatory markers, such as IL-6, D-dimer and ferritin (34). Lechuga et al (34) also suggested that the haematological changes associated with long COVID-19 may have implications for the diagnosis, monitoring, and therapy of patients with this disease. Furthermore, Mertens and Peñalvo (35) reported that countries where malnutrition is common and may serve as a driving factor for causing the mortality of patients infected with SARS-CoV-2. Their study reported a moderate positive association between COVID-19 severity and anaemia. They concluded that there was an association between anaemia and an increased risk of developing severe COVID-19(35). Anaemic patients have reduced concentrations of haemoglobin, which transports oxygen to different parts of the body (35). This oxygen transportation is disrupted when the haemoglobin level is low. This usually results in hypoxia, leading to multiple organ dysfunction, including the organs of the respiratory system. This scenario increases the severity of COVID-19, as regards symptoms and outcomes (36). The iron deficiency can result in IDA and increase susceptibility to infection via the suppression of the immune response against pathogens (33,37). The association between iron and infections is not yet fully understood however, and requires further investigations. Previous research has reported that iron deficiency predisposes individuals to infections (38), and studies have also proposed the protective effects of iron (38,39). Therefore, the most efficient strategy to prevent COVID-19 is the maintenance of iron homeostasis (38).

In the present study, the number of patients with a history of stroke was greater in the IDA group in comparison to the non-IDA patients. This result is consistent with the findings of a previous study (40). Chang et al (41) investigated the link between stroke and IDA. IDA has been reported to augment the risk of ischemic stroke as it disrupts the transport of oxygen to different tissues via the reduction of haemoglobin (41). In IDA, the secretion of erythropoietin increases the number of RBCs. This secretion stimulates the formation of platelets, leading to thrombocytosis and thrombus formation (42).

In the present study, the results also revealed that the number of patients exhibiting increased blood pressure was also considerably greater in the IDA group as compared with the non-IDA group. This is in line with the study by Savarese et al (43), which reported that a deficiency of iron is common in patients with cardiovascular disease (43), and the study by Lanser et al (44), which also reported an association of anaemia with cardiovascular disease.

The results of the present study also demonstrated that the patients with IDA had reduced rates of cough as compared with non-IDA COVID-19 patients. The potential association between serum iron and COVID-19 severity was previously investigated by Zhao et al (45). They reported that the insufficiency of iron may be one of the factors causing cough in the majority of individuals infected with COVID-19. The result in the present study is in contrast with that in the study by Zhao et al (45). The reduced rates of cough among the patients with IDA observed in the present study may be due to the rapid delivery of medical care given to patients at the hospital. Nevertheless, these results are substantially in agreement with those of Zhao et al (45), namely that the decreased concentration of serum iron was an independent risk factor for COVID-19.

The present study also demonstrated that IDA was associated with a longer period of hospitalization and with a greater number of complications, eventually necessitating admission into ICUs. Herein, the number of patients with IDA discharged without complications was lower than that of non-IDA patients discharged without complications. It is therefore highly recommended that anaemic patients should be instructed to strongly adhere to the precautionary measures to prevent the infections. Moreover, physicians should closely monitor anaemic patients to avoid adverse outcomes due to COVID-19. Anaemia may be considered one of the factors in the development of risk stratification models for COVID-19 in the future.

The present study had certain limitations, which should be mentioned. The present study was a single-centre study with a limited sample size. The association between IDA and COVID-19 needs to be further be investigated in multicentre, larger-scales studies to verify the findings presented herein.

In conclusion, the present study demonstrated significant associations between IDA and longer periods of hospitalization, and a greater incidence of complications in hospitalised patients with SARS-COV-2. However, the results should be interpreted with caution, given the retrospective nature of the study and the constraints on data collection. Considering the notable effect of IDA on different aspects of COVID-19 revealed in the present study, screening tests need to be carried out to identify patients with IDA followed by the treatment of IDA to improve patient outcomes. IDA can be treated through blood transfusions, the administration of iron supplements or other strategies. Moreover, different measures need to be taken to prevent and treat cases with IDA against viral infection.

Supplementary Material

Supplementary Data.

Acknowledgements

The authors would like to thank King Fahad Specialist Hospital, Tabuk, Saudi Arabia for providing excellent advice and the use of facilities.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MMJ and MMA were involved in the conceptualization of the study, in sample collection, data analysis and in the writing of the manuscript. AAA and MAA were involved in the conceptualization of the study, in sample collection and in the writing of the manuscript. ASM, AJA, NAA, RAA, WSA and YAA were involved in the conceptualization of the study and in sample collection. MA was involved in the conceptualization of the study and in data analysis. IE was involved in the conceptualization of the study, in the writing and editing of the manuscript, and in data analysis. RM was involved in the conceptualization of the study, in data analysis, in the writing and editing of the manuscript, and in project administration. All authors have read and approved the final manuscript. MMJ and MMA confirm the authenticity of all the raw data.

Ethics approval and consent to participate

The present study was conducted according to the guidelines outlined in the Declaration of Helsinki and received two ethical approvals from the University of Tabuk Research Ethics Committee (Tabuk, Saudi Arabia; Registration no. UT-198-52-2022) and from the Institutional Review Board General Directorate of Health Affairs, Tabuk Region (Registration no. 612-43-006198). Ethical approvals include agreement for data gathering using data collection forms that include only laboratory results and organized by unique numbers.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Table I Characteristics of the demographic data and comorbidities among the overall cohort and among patients with and without IDA.

 	IDA	
Parameter	Category	Overall, n=100 (%)	No, n=77 (%)	Yes, n=23 (%)	P-value	
Age, years	18 to <30	21 (21.0)	18 (23.4)	3 (13.0)	0.340	
 	30 to <45	19 (19.0)	16 (20.8)	3 (13.0)	 	
 	45 to <60	41 (41.0)	31 (40.3)	10 (43.5)	 	
 	≥60	19 (19.0)	12 (15.6)	7 (30.4)	 	
Sex	Male	45 (45.0)	36 (46.8)	9 (39.1)	0.519	
 	Female	55 (55.0)	41 (53.2)	14 (60.9)	 	
Smoking	No	63 (63.0)	48 (62.3)	15 (65.2)	>0.999	
 	Yes	24 (24.0)	19 (24.7)	5 (21.7)	 	
 	Do not know	13 (13.0)	10 (13.0)	3 (13.0)	 	
Unit patient admitted to	Isolation unit	61 (61.0)	54 (70.1)	7 (30.4)	<0.001	
 	ICU	39 (39.0)	23 (29.9)	16 (69.6)	 	
Comorbidities	Non-IDA anaemia	6 (6.0)	5 (6.5)	1 (4.3)	>0.999	
 	Angina	5 (5.0)	3 (3.9)	2 (8.7)	0.324	
 	Heart problems	17 (17.0)	10 (13.0)	7 (30.4)	0.063	
 	Asthma	10 (10.0)	10 (13.0)	0 (0.0)	0.111	
 	Cancer	4 (4.0)	3 (3.9)	1 (4.3)	>0.999	
 	Stomach or peptic ulcer	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	Hypertension	29 (29.0)	19 (24.7)	10 (43.5)	0.081	
 	COPD	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	Diabetes	23 (23.0)	16 (20.8)	7 (30.4)	0.334	
 	ARF type 2	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	Epilepsy	3 (3.0)	2 (2.6)	1 (4.3)	0.548	
 	OSA	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	kidney disease	3 (3.0)	3 (3.9)	0 (0.0)	>0.999	
 	Lung fibrosis	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
 	High cholesterol	7 (7.0)	5 (6.5)	2 (8.7)	0.659	
 	Surgery	11 (11.0)	6 (7.8)	5 (21.7)	0.120	
 	Pneumonia	10 (10.0)	7 (9.1)	3 (13.0)	0.692	
 	Stroke	6 (6.0)	2 (2.6)	4 (17.4)	0.024	
 	Mature cataract	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	ARDS	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
 	Leukaemia	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
 	Hereditary sensory motor neuropathy	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
 	MV REGURG	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Data were analysed using the Chi-squared test or Fisher's exact test. Values in bold font indicate statistically significant differences (P<0.05). IDA, iron deficiency anaemia; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; ARF, acute respiratory failure; OSA, obstructive sleep apnoea; ARDS, acute respiratory distress syndrome; MV REGURG, mitral valve regurgitation.

Table II Characteristics of blood and iron profiles among the included patients.

Parameter	Category	n (%)	
Haemoglobin	Normal	33 (33.0)	
 	Low	51 (51.0)	
 	High	16 (16.0)	
RBC count	Normal	43 (43.0)	
 	Low	46 (46.0)	
 	High	11 (11.0)	
WBC count	Normal	33 (33.0)	
 	Low	5 (5.0)	
 	High	62 (62.0)	
Platelet count	Normal	58 (58.0)	
 	Low	15 (15.0)	
 	High	27 (27.0)	
MCV	Normal	52 (52.0)	
 	Low	39 (39.0)	
 	High	9 (9.0)	
MCH	Normal	50 (50.0)	
 	Low	45 (45.0)	
 	High	5 (5.0)	
MCHC	Normal	53 (53.0)	
 	Low	46 (46.0)	
 	High	1 (1.0)	
Serum iron	Normal	54 (54.0)	
 	Low	40 (40.0)	
 	High	6 (6.0)	
Transferrin	Normal	55 (55.0)	
 	Low	42 (42.0)	
 	High	3 (3.0)	
Ferritin	Normal	35 (35.0)	
 	Low	28 (28.0)	
 	High	37 (37.0)	
TIBC	Normal	54 (54.0)	
 	Low	15 (15.0)	
 	High	31 (31.0)	
Transferrin saturation (%)	Normal	56 (56.0)	
 	Low	41 (41.0)	
 	High	3 (3.0)	
RBC, red blood cell; WBC, white blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; TIBC, total iron-binding capacity.

Table III Presenting symptoms and diagnosis of upon admission among the overall cohort and among patients with and without IDA.

 	IDA	
Parameter	Overall, n=100 (%)	No, n=77 (%)	Yes, n=23 (%)	P-value	
Cough	25 (25.0)	24 (31.2)	1 (4.3)	0.009	
SOB	20 (20.0)	14 (18.2)	6 (26.1)	0.391	
High blood pressure	12 (12.0)	6 (7.8)	6 (26.1)	0.028	
Fever	10 (10.0)	9 (11.7)	1 (4.3)	0.446	
COVID-19 (mortality)	11 (11.0)	9 (11.7)	2 (8.7)	>0.999	
Asthma	8 (8.0)	8 (10.4)	0 (0.0)	0.192	
Chest pain	7 (7.0)	6 (7.8)	1 (4.3)	>0.999	
Pneumonia	5 (5.0)	3 (3.9)	2 (8.7)	0.324	
ARDS	3 (3.0)	2 (2.6)	1 (4.3)	0.548	
Nausea	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Loss of appetite	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Acute bronchitis	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Dyspnoea	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Oesophageal varices bleeding	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
CVA	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Renal failure	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Myocardial infarction	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
COPD	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Mature cataract	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Thrombosis	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
AF	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Stroke	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Ischemic cardiomyopathy	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Anal fistula	1 (1.0)	0 (0.0)	1 (4.3)	0.230	
Acute respiratory failure type 2	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
CAD	1 (1.0)	1 (1.3)	0 (0.0)	>0.999	
Data were analysed using the Chi-squared test or Fisher's exact test. Values in bold font indicate statistically significant differences (P<0.05). IDA, iron deficiency anaemia; COPD, chronic obstructive pulmonary disease; SOB, shortness of breath; ARDS, acute respiratory distress syndrome; CVA, cerebral vascular accident; AF, atrial fibrillation; CAD, coronary artery disease.

Table IV Outcomes of the overall cohort and patients with and without IDA.

 	IDA	
Parameter	Overall, n=100	No, n=77	Yes, n=23	P-value	
Hospitalization period (days)a	7 (4-15)	5 (3-10)	15 (8-22)	<0.001	
Discharged with no complications	52 (52.0%)	46 (59.7%)	6 (26.1%)	0.005	
ARDS	1 (1.0%)	1 (1.3%)	0 (0.0%)	>0.999	
Pneumonia	4 (4.0%)	3 (3.9%)	1 (4.3%)	>0.999	
Septic shock	3 (3.0%)	1 (1.3%)	2 (8.7%)	0.131	
Multi-organ failure	2 (2.0%)	1 (1.3%)	1 (4.3%)	0.409	
Death	11 (11.0%)	7 (9.1%)	4 (17.4%)	0.271	
aResults are expressed as the median (interquartile range); otherwise, the results are presented as frequencies and percentages. Data were analysed using the Wilcoxon rank-sum test, Chi-squared test, or Fisher's exact test. Values in bold font indicate statistically significant differences (P<0.05). IDA, iron deficiency anaemia; ARDS, acute respiratory distress syndrome.

Table V Outcomes of patients with and without IDA.

 	IDA	
Parameter	Overall, n=100 (%)	No, n=77 (%)	Yes, n=23 (%)	P-value	
Mortality	11 (11.0)	7 (9.1)	4 (17.4)	0.271	
ICU	39 (39.0)	23 (29.9)	16 (69.6)	<0.001	
Discharged with no complications	52 (52.0)	46 (59.7)	6 (26.1)	0.005	
Suffering from complications	37 (37.0)	25 (32.5)	12 (52.2)	0.086	
Data were analysed using the Chi-squared test or Fisher's exact test. Values in bold font indicate statistically significant differences (P<0.05). IDA, iron deficiency anaemia; ICU, intensive care unit.
==== Refs
References

1 Yin Y Wunderink RG MERS, SARS and other coronaviruses as causes of pneumonia Respirology 23 130 137 2018 10.1111/resp.13196 29052924
2 Peng PWH Ho PL Hota SS Outbreak of a new coronavirus: What anaesthetists should know Br J Anaesth 124 497 501 2020 10.1016/j.bja.2020.02.008 32115186
3 World Health Organization: Weekly epidemiological update on COVID-19-22 February 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-22-february-2022.
4 Nurunnabi M The preventive strategies of COVID-19 pandemic in Saudi Arabia J Microbiol Immunol Infect 54 127 128 2021 10.1016/j.jmii.2020.07.023 32807687
5 Salam AA Al-Khraif RM Elsegaey I COVID-19 in saudi arabia: An overview Front Public Health 9 736942 2021 10.3389/fpubh.2021.736942 35186861
6 World Health Organization: COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum. https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum.
7 Singhal T A review of coronavirus Disease-2019 (COVID-19) Indian J Pediatr 87 281 286 2020 10.1007/s12098-020-03263-6 32166607
8 Smatti MK Al Thani AA Yassine HM Viral-induced enhanced disease illness Front Microbiol 9 2991 2018 10.3389/fmicb.2018.02991 30568643
9 Wu Z McGoogan JM Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention JAMA 323 1239 1242 2020 10.1001/jama.2020.2648 32091533
10 Bi Q Wu Y Mei S Ye C Zou X Zhang Z Liu X Wei L Truelove SA Zhang T Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study Lancet Infect Dis 20 911 919 2020 10.1016/S1473-3099(20)30287-5 32353347
11 Murthy S Gomersall CD Fowler RA Care for Critically Ill patients With COVID-19 JAMA 323 1499 1500 2020 10.1001/jama.2020.3633 32159735
12 Yang J Zheng Y Gou X Pu K Chen Z Guo Q Ji R Wang H Wang Y Zhou Y Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis Int J Infect Dis 94 91 95 2020 10.1016/j.ijid.2020.03.017 32173574
13 Lippi G Henry BM Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med 167 105941 2020 10.1016/j.rmed.2020.105941 32421537
14 Zhou F Yu T Du R Fan G Liu Y Liu Z Xiang J Wang Y Song B Gu X Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study Lancet 395 1054 1062 2020 10.1016/S0140-6736(20)30566-3 32171076
15 Herold T Jurinovic V Arnreich C Lipworth BJ Hellmuth JC von Bergwelt-Baildon M Klein M Weinberger T Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 J Allergy Clin Immunol 146 128 136.e4 2020 10.1016/j.jaci.2020.05.008 32425269
16 Henry BM de Oliveira MHS Benoit S Plebani M Lippi G Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis Clin Chem Lab Med 58 1021 1028 2020 10.1515/cclm-2020-0369 32286245
17 Theurl I Aigner E Theurl M Nairz M Seifert M Schroll A Sonnweber T Eberwein L Witcher DR Murphy AT Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications Blood 113 5277 5286 2009 10.1182/blood-2008-12-195651 19293425
18 Weiss G Ganz T Goodnough LT Anemia of inflammation Blood 133 40 50 2019 10.1182/blood-2018-06-856500 30401705
19 Camaschella C Iron deficiency Blood 133 30 39 2019 10.1182/blood-2018-05-815944 30401704
20 Cappellini MD Comin-Colet J de Francisco A Dignass A Doehner W Lam CS Macdougall IC Rogler G Camaschella C Kadir R Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management Am J Hematol 92 1068 1078 2017 10.1002/ajh.24820 28612425
21 Wouters H van der Klauw MM de Witte T Stauder R Swinkels DW Wolffenbuttel BHR Huls G Association of anemia with health-related quality of life and survival: A large population-based cohort study Haematologica 104 468 476 2019 10.3324/haematol.2018.195552 30309850
22 Brigham EP McCormack MC Takemoto CM Matsui EC Iron status is associated with asthma and lung function in US women PLoS One 10 e0117545 2015 10.1371/journal.pone.0117545 25689633
23 Bergamaschi G Borrelli de Andreis F Aronico N Lenti MV Barteselli C Merli S Pellegrino I Coppola L Cremonte EM Croce G Anemia in patients with Covid-19: Pathogenesis and clinical significance Clin Exp Med 21 239 246 2021 10.1007/s10238-020-00679-4 33417082
24 Faghih Dinevari M Somi MH Sadeghi Majd E Abbasalizad Farhangi M Nikniaz Z Anemia predicts poor outcomes of COVID-19 in hospitalized patients: A prospective study in Iran BMC Infect Dis 21 170 2021 10.1186/s12879-021-05868-4 33568084
25 McLean E Cogswell M Egli I Wojdyla D de Benoist B Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005 Public Health Nutr 12 444 454 2009 10.1017/S1368980008002401 18498676
26 Taneri PE Gomez-Ochoa SA Llanaj E Raguindin PF Rojas LZ Roa-Diaz ZM Salvador D Jr Groothof D Minder B Kopp-Heim D Anemia and iron metabolism in COVID-19: A systematic review and meta-analysis Eur J Epidemiol 35 763 773 2020 10.1007/s10654-020-00678-5 32816244
27 Kumar A Sharma E Marley A Samaan MA Brookes MJ Iron deficiency anaemia: Pathophysiology, assessment, practical management BMJ Open Gastroenterol 9 e000759 2022 10.1136/bmjgast-2021-000759 34996762
28 Suriawinata E Mehta KJ Iron and iron-related proteins in COVID-19 Clin Exp Med 23 969 991 2023 10.1007/s10238-022-00851-y 35849261
29 Hubacek JA Philipp T Adamkova V Majek O Dusek L A haemochromatosis-causing HFE mutation is associated with SARS-CoV-2 susceptibility in the Czech population Clin Chim Acta 538 211 215 2023 10.1016/j.cca.2022.12.025 36572138
30 Mir R Elfaki I Alanazi MA Algehainy NA Altemani FH Alsayed BA Mohamed EI Mustafa SK Moawadh MS Tayeb FJ Whole-Exome sequencing detecting a recurrent pathogenic mutation, HFE p.His63Asp (H63D) in COVID-19 patients and its effect on mortality Discov Med 36 1513 1526 2024 10.24976/Discov.Med.202436186.140 39054721
31 Reuben A Chung JW Lapointe R Santos MM The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system Immun Inflamm Dis 5 218 232 2017 10.1002/iid3.158 28474781
32 Zhou ZD Tan EK Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases Mol Neurodegener 12 75 2017 10.1186/s13024-017-0218-4 29061112
33 Jonker FA Boele van Hensbroek M Anaemia, iron deficiency and susceptibility to infections J Infect 69 (Suppl 1) S23 S27 2014 10.1016/j.jinf.2014.08.007 25264159
34 Lechuga GC Morel CM De-Simone SG Hematological alterations associated with long COVID-19 Front Physiol 14 1203472 2023 10.3389/fphys.2023.1203472 37565145
35 Mertens E Penalvo JL The Burden of Malnutrition and Fatal COVID-19: A global burden of disease analysis Front Nutr 7 619850 2020 10.3389/fnut.2020.619850 33553234
36 Hariyanto TI Kurniawan A Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection Transfus Apher Sci 59 102926 2020 10.1016/j.transci.2020.102926 32893135
37 Aslan ES Aydin H Tekin YK Keles S White KN Hekim N Association between iron metabolism and SARS-COV-2 infection, determined by ferritin, hephaestin and hypoxia-induced factor-1 alpha levels in COVID-19 patients Mol Biol Rep 50 2471 2478 2023 10.1007/s11033-022-08221-3 36600108
38 Morais AHA Aquino JS da Silva-Maia JK Vale SHL Maciel BLL Passos TS Nutritional status, diet and viral respiratory infections: Perspectives for severe acute respiratory syndrome coronavirus 2 Br J Nutr 125 851 862 2021 10.1017/S0007114520003311 32843118
39 Menshawey R Menshawey E Alserr AHK Abdelmassih AF Low iron mitigates viral survival: Insights from evolution, genetics, and pandemics-a review of current hypothesis Egypt J Med Hum Genet 21 75 2020 10.1186/s43042-020-00114-z 38624521
40 Desai A Oh D Rao EM Sahoo S Mahajan UV Labak CM Mauria R Shah VS Nguyen Q Herring EZ Impact of anemia on acute ischemic stroke outcomes: A systematic review of the literature PLoS One 18 e0280025 2023 10.1371/journal.pone.0280025 36603022
41 Chang YL Hung SH Ling W Lin HC Li HC Chung SD Association between ischemic stroke and iron-deficiency anemia: A population-based study PLoS One 8 e82952 2013 10.1371/journal.pone.0082952 24349404
42 Heo J Youk TM Seo KD Anemia is a risk factor for the development of ischemic stroke and Post-Stroke mortality J Clin Med 10 2556 2021 10.3390/jcm10122556 34207841
43 Savarese G von Haehling S Butler J Cleland JGF Ponikowski P Anker SD Iron deficiency and cardiovascular disease Eur Heart J 44 14 27 2023 10.1093/eurheartj/ehac569 36282723
44 Lanser L Fuchs D Scharnagl H Grammer T Kleber ME März W Weiss G Kurz K Anemia of chronic disease in patients with cardiovascular disease Front Cardiovasc Med 8 666638 2021 10.3389/fcvm.2021.666638 34458328
45 Zhao K Huang J Dai D Feng Y Liu L Nie S Serum iron level as a potential predictor of coronavirus disease 2019 severity and mortality: A retrospective study Open Forum Infect Dis 7 ofaa250 2020 10.1093/ofid/ofaa250 32661499
